Randall Michael Giuffre - Net Worth and Insider Trading

Randall Michael Giuffre Net Worth

The estimated net worth of Randall Michael Giuffre is at least $2 Million dollars as of 2024-11-08. Randall Michael Giuffre is the Director of DiaMedica Therapeutics Inc and owns about 391,998 shares of DiaMedica Therapeutics Inc (DMAC) stock worth over $2 Million. Details can be seen in Randall Michael Giuffre's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Randall Michael Giuffre has not made any transactions after 2023-06-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Randall Michael Giuffre

To

Randall Michael Giuffre Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Randall Michael Giuffre owns 1 companies in total, including DiaMedica Therapeutics Inc (DMAC) .

Click here to see the complete history of Randall Michael Giuffre’s form 4 insider trades.

Insider Ownership Summary of Randall Michael Giuffre

Ticker Comapny Transaction Date Type of Owner
DMAC DiaMedica Therapeutics Inc 2023-06-23 director

Randall Michael Giuffre Latest Holdings Summary

Randall Michael Giuffre currently owns a total of 1 stock. Randall Michael Giuffre owns 391,998 shares of DiaMedica Therapeutics Inc (DMAC) as of June 23, 2023, with a value of $2 Million.

Latest Holdings of Randall Michael Giuffre

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DMAC DiaMedica Therapeutics Inc 2023-06-23 391,998 4.18 1,636,592

Holding Weightings of Randall Michael Giuffre


Randall Michael Giuffre Form 4 Trading Tracker

According to the SEC Form 4 filings, Randall Michael Giuffre has made a total of 6 transactions in DiaMedica Therapeutics Inc (DMAC) over the past 5 years, including 6 buys and 0 sells. The most-recent trade in DiaMedica Therapeutics Inc is the acquisition of 65,000 shares on June 23, 2023, which cost Randall Michael Giuffre around $254,150.

Insider Trading History of Randall Michael Giuffre

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Randall Michael Giuffre Trading Performance

GuruFocus tracks the stock performance after each of Randall Michael Giuffre's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Randall Michael Giuffre is 35.28%. GuruFocus also compares Randall Michael Giuffre's trading performance to market benchmark return within the same time period. The performance of stocks bought by Randall Michael Giuffre within 3 months outperforms 5 times out of 7 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Randall Michael Giuffre's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Randall Michael Giuffre

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
4 out of 7 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 19.57 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 20.52 LIMIT LIMIT LIMIT LIMIT LIMIT

Randall Michael Giuffre Ownership Network

Ownership Network List of Randall Michael Giuffre

No Data

Ownership Network Relation of Randall Michael Giuffre

Insider Network Chart

Randall Michael Giuffre Owned Company Details

What does DiaMedica Therapeutics Inc do?

Who are the key executives at DiaMedica Therapeutics Inc?

Randall Michael Giuffre is the director of DiaMedica Therapeutics Inc. Other key executives at DiaMedica Therapeutics Inc include 10 percent owner Jan Stahlberg , 10 percent owner Koch Thomas Von , and CFO and Secretary Scott Kellen .

DiaMedica Therapeutics Inc (DMAC) Insider Trades Summary

Over the past 18 months, Randall Michael Giuffre made 1 insider transaction in DiaMedica Therapeutics Inc (DMAC) with a net purchase of 65,000. Other recent insider transactions involving DiaMedica Therapeutics Inc (DMAC) include a net purchase of 2,670,588 shares made by Koch Thomas Von , a net purchase of 58,364 shares made by David J. Wambeke , and a net purchase of 1,200,000 shares made by Jan Stahlberg .

In summary, during the past 3 months, insiders sold 0 shares of DiaMedica Therapeutics Inc (DMAC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of DiaMedica Therapeutics Inc (DMAC) were sold and 4,067,889 shares were bought by its insiders, resulting in a net purchase of 4,067,889 shares.

DiaMedica Therapeutics Inc (DMAC)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

DiaMedica Therapeutics Inc Insider Transactions

No Available Data

Randall Michael Giuffre Mailing Address

Above is the net worth, insider trading, and ownership report for Randall Michael Giuffre. You might contact Randall Michael Giuffre via mailing address: 2 Carlson Parkway, Suite 260, Minneapolis Mn 55447.